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A study on blocking store-operated Ca2+ entry in pulmonary 
arterial smooth muscle cells with xyloketals from marine fungi
In this study, the effect of four xyloketals 1-4 on store-opera-
ted calcium entry (SOCE) was investigated in primary distal 
pulmonary arterial smooth muscle cells (PASMCs) isolated 
from mice. The results showed that xyloketal A (1), an un-
usual ketal with C-3 symmetry, exhibited strong SOCE 
blocking activity. Secretion of interleukin-8 (IL-8) was also 
inhibited by xyloketal A. The parallel artificial membrane 
permeability assay (PAMPA) of 1-4 suggested that these 
xyloketals penetrated easily through the cell membrane. 
Moreover, the molecular docking study of xyloketal A with 
activation region of the stromal interaction molecule 
(STIM) 1 and the calcium release-activated calcium modu-
lator (ORAI) 1 (STIM1-ORAI1) protein complex, the key 
domain of SOCE, revealed that xyloketal A exhibited a non-
covalent interaction with the key residue lysine 363 (LYS363) 
in the identified cytosolic regions in STIM1-C. These find-
ings provided useful information about xyloketal A as a 
SOCE inhibitor for further evaluation.
Keywords: xyloketal A, store-operated calcium entry, mo-
lecular docking, IL-8, parallel artificial membrane perme-
ability assay
Store-operated calcium entry (SOCE) is the central mechanism in cellular calcium 
signaling and in maintaining cellular calcium balance. It plays an important role in regu-
lating calcium signaling and cellular responses in different cell types, such as airway 
smooth muscle cells (ASMCs) (1), polarized cells (2), endothelial cells (3), and pulmonary 
arterial smooth muscle cells (PASMCs) (4, 5). Along this line, SOCE deregulation is in-
volved in the development of various diseases, such as hypertension (6, 7), stroke (8, 9), 
diabetes (10), cancer (11–14), pulmonary arterial hypertension (PAH) (15), and others (16, 
17). Experiments have revealed the essential role of stromal interaction molecule (STIM) 1 
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activated calcium channel protein 1 (named ORAI1) in mediating SOCE because these 
proteins sense and respond to endoplasmic reticulum calcium store depletion (18).
PAH is a rare life-threatening disease, and although significant progress has been made 
in the past decades in our understanding of PAH pathophysiology and treatment, the prog-
nosis is still poor. It was previously demonstrated in PASMC that influx of Ca2+ through 
transient receptor potential (TRP) proteins is likely to play a significant role in the develop-
ment of chronic hypoxic PAH (15). In line with recent discoveries of the STIM1-ORAI1 role 
in SOCE, it seems that these proteins may serve as important targets for PAH treatment.
Marine environment is a rich source of novel compounds and unusual secondary me-
tabolites, many of which show promise as therapeutic agents. Xyloketals, a type of novel 
compounds possessing unique molecular structures, were isolated from the marine man-
grove fungus Xylaria sp. (19, 20). In particular, xyloketal A is a unique ketal compound with 
C-3 symmetry with cis-junction between tetrahydropyrane and tetrahydrofurane. We have 
previously demonstrated that xyloketals show a variety of activities, such as antioxidant (21), 
promoting endothelial cell nitric oxide (NO) production, inhibiting NADPH oxidase, and 
L-calcium channel blocking in different disease models (22–24). Xyloketals have been previ-
ously reported to inhibit Ca2+ influx through blockade of L-type calcium channels, which 
raises the possibility that xyloketals might affect calcium signaling in diseases like chronic 
hypoxic pulmonary hypertension. We have therefore investigated the potential of a series of 
xyloketals: xyloketal A (1), xyloketal B (2), and other two xyloketal derivatives (3 and 4) (Fig. 
1) on SOCE in primary distal pulmonary arterial smooth muscle cells (PASMCs) isolated 
from mice. In addition, their effect on secretion of interleukin-8 (IL-8), an important pro-
inflammatory chemokine in airway epithelia, was tested. A parallel artificial membrane 
permeability assay (PAMPA) of these xyloketals was carried out to explore their permeabi-
lity. Further, a molecular docking study of a selected compound with STIM-ORAI activating 
region (SOAR) was performed to characterize their interactions.
EXPERIMENTAL
Reagents
Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) were 
purchased from Gibco, USA. All other reagents utilized were purchased from Sigma 
Fig. 1. Structures of xyloketal A (1), xyloketal B (2) and two xyloketal derivatives 3 and 4.
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Chemical Co. USA, unless otherwise specified. Xyloketals 1-4 were obtained from the 
School of Chemistry, Sun Yat-Sen University, Guangzhou, China. Identity and purity of 
the compounds were determined using HPLC (high performance liquid chromatography) 
and NMR, as previously described (19, 23), and were > 95 %. Xyloketals were dissolved in 
dimethyl sulfoxide (DMSO) and stored at –20 °C until use. Final concentration of DMSO in 
the culture media was ≤ 0.1 %.
PASMCs cells’ isolation and culture
Distal intrapulmonary arteries and intrapulmonary veins were dissected from the 
lungs of adult male C57BL/6 mice (20–25 g) purchased from the Guangdong Medical Labo-
ratory Animal Center (Guangzhou, Guandong, China). All animal experiments were ap-
proved by the Animal Care and Use Committee of Sun Yat-sen University, and all animal 
care and experimental procedures strictly followed the Council for International Organi-
zations of Medical Sciences (CIOMS) guidelines. Primary cultures of PASMCs were pre-
pared from the lungs of animals. Briefly, animals were humanely killed by cervical dislo-
cation. Distal (> 4th generation) intrapulmonary arteries were dissected from the lungs. A 
thin layer of adventitia was carefully stripped off with fine forceps, and the endothelium 
was wiped off using a cotton swab. Lumina were gently swiped using a cotton swab to 
remove endothelium. Distal PASMCs were obtained from the isolated pulmonary arteries 
(PA) by enzymatic dissociation (papain and collagenase IA, Sigma-Aldrich, USA) in me-
dium according to the described protocol (25, 26). Purity was > 98 %, which was checked 
by the morphological appearance under phase-contrast microscopy (IX73, Olympus, Ja-
pan). Isolated cells were then seeded in 6-well culture dishes and cultured in smooth 
muscle growth medium-2 (Clonetics, USA) in a humidified atmosphere of 5 % CO2 and 
95 % air at 37 ºC for 3 to 4 days. PASMCs were replaced with smooth muscle basal medium 
(Clonetics) containing 0.3 % FBS for 24 h to reach growth arrest for the treatment of sub-
stances. Before measuring the intracellular Ca2+ concentration, PASMCs were treated with 
compounds 1-4 (5 mmol L–1) for 4–6 h.
Measurement of intracellular Ca2+
Intracellular Ca2+ concentration was measured according to the reported protocol (27, 
28). Coverslips with PASMCs were incubated with 5 µmol L–1 calcium indicator fura-2 
acetoxymethyl ester (Invitrogen, USA) for 60 min at 37 °C with 5 % CO2-95 % air, mounted 
in a closed polycarbonate chamber and clamped to a heated aluminum platform (PH-2, 
Warner Instrument, USA) on the stage of a Nikon TSE 100 Ellipse inverted microscope 
(Nikon, USA). The chamber was perfused with Krebs Ringer bicarbonate (KRB) solution 
equilibrated with 16 % O2 and 5 % CO2 at 38 °C at 0.5–1 mL min–1 in heated reservoirs. 
Perfusate was led via stainless steel tubing and a manifold to an inline heat exchanger (SF-
28, Warner Instrument) to rewarm the perfusate just before it entered the cell chamber. 
Temperature of the heat exchanger and chamber platform was controlled by a dual-chan-
nel heater controller (TC-344B, Warner Instrument). To remove the extracellular dye and to 
allow the intracellular esterases to cleave cytosolic fura-2-AM into active fura-2, the cells 
were perfused with modified Krebs solution for 10–15 min. Fura-2 fluorescence was ob-
served as a 510-nm light emission with excitation wavelengths of 340 and 380 nm. Intracel-
lular Ca2+ concentration ([Ca2+]i) was determined at 12- to 30-s intervals from the ratio of 
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fura-2 fluorescence after excitation at 340 nm to that after excitation at 380 nm (F340/F380) in 
20–30 cells using a fluorescence imaging system that consisted of a xenon arc lamp, inter-
ference filters, an electronic shutter, a 20× fluorescence objective and a cooled charge-cou-
pled device imaging camera. Data were collected using InCyte software (Intracellular Im-
aging Inc, USA). In all experiments, multiple cells were imaged in a single field and one 
randomly chosen peripheral cytosolic area from each cell was averaged. Resting [Ca2+]i was 
obtained by average F340/F380 during the initial modified Krebs solution (MKS) recording. 
Changes in [Ca2+]i were calculated as peak F340/F380 minus the averaged steady-state F340/
F380 in the 20 s preceding the rise to a peak. All time periods under each condition were 
kept constant during the experiments (27).
Assessment of SOCE
We assessed SOCE after Ca2+ restoration according to the described protocol (27, 28). 
Briefly, PASMCs were perfused for 10-15 min with Ca2+-free KRB solution containing 5 
mmol L–1 nifedipine, 10 mmol L–1 cyclopiazonic acid (CPA), and 1 mmol L–1 ethylenediami-
netetraacetic acid (EDTA). We first measured [Ca2+]i at 0–5 min intervals before and after 
restoration of extracellular [Ca2+] to 2.5 mmol L–1. SOCE was evaluated from the increase 
in [Ca2+]i caused by restoration of extracellular [Ca2+]i.
Preparation of cigarette smoke extraction (CSE) and cell stimulation
CSE was prepared by bubbling smoke from 2 cigarettes (purchased from Guangzhou, 
China, with ~0.8 mg nicotine per cigarette) into 10 mL of serum-free DMEM and then CSE 
was sterile-filtered through a 0.2-mm filter (VWR International, USA). This medium was 
defined as 100 % CSE while with the concentration of 1 % CSE cell inflammation was in-
duced. Human bronchial epithelial cells Beas-2b and 16 HBE (purchased from ATCC, 
Manassas, VA, USA) were grown in high-glucose DMEM medium, with 10 % fetal bovine 
serum, 100 U mL–1 penicillin and 0.1 mg mL–1 streptomycin. Cells were first treated with 
xyloketal A 5 mmol L–1 for 2 h, and then 1 or 2 % CSE was added for 24 h.
Enzyme-linked immunosorbent assay (ELISA) for IL-8 detection
Cultured media were collected at the end of experimental procedures. Levels of IL-8 
secreted from cultured cells were quantified using the IL-8 Elisa kit (BD Biosciences, USA) 
according to the manufacturer’s protocol.
Parallel artificial membrane permeability assay (PAMPA)
In PAMPA, a „sandwich” structure was formed by a 96-well microtiter plate and a 
96-well filter plate, coated with dried 15 µL of 10 % m/V lecithin/dodecane (Egg-PAMPA) 
or 5 % m/V hexadecane/dodecane (HDM-PAMPA) according to the protocol described in 
ref. 29. Solutions of xyloketals 1-4 together with the positive controls verapamil, atenolol 
and ciprofloxacin were added to the wells (100 µL per well) on a pre-coated filter, and 
phosphate buffer saline (pH 7.4) was added to the wells (375 µL per well) on the receiver 
plate. Filter plate was coupled with the receiver plate and the sandwich was incubated in 
the thermostat at 37 °C for 16 h or 5 h under shaking at 80 rpm. After incubation, the plates 
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were separated and sample solutions from each well of both the filter plate and the re-


















where VD is the donor compartment volume, VA is the acceptor compartment volume, A is 
the effective area of the membrane insert and t is time. Here, A is 0.28 cm2, [drug]acc refers 
to the concentration of the tested drug in the acceptor compartment, [drug]eq is the concen-
tration of the tested drug in the equilibrium mixture, and time is the total transport time 
in seconds. Technical specification is in Egg-PAMPA, membrane permeability log Pe > –5.0 
is easily permeable, –5.0 > log Pe > –6.0 is moderately permeable, and log Pe < –6.0 is hardly 
permeable. In HDM-PAMPA, membrane permeability of log Pe > –4.0 is easily permeable; 
–4.0 > log Pe > –5.0 is moderately permeable, and log Pe < –5.0 is hardly permeable.
The HPLC (LC-2010, Shimadzu, Japan, equipped with UV detector) method was de-
scribed in a previous study (30). The injection volume was 20 µL and the detector wave-
length was set at 345 nm. Chromatographic separation was carried out on a Phenomenex 
C18 column (4.6 mm × 250 mm, 5 µm) associated with a C18 pre-column (Phenomenex, 
USA). The mobile phase consisted of methanol-acetonitrile-water (30:30:40, V/V/V); iso-
cratic elution was used. The flow rate was 0.8 ml min–1. All solutions were filtered under 
vacuum through a 0.45-µm membrane filter and degassed ultrasonically before used.
Molecular docking studies of 3TER and xyloketal
Molecular docking was evaluated using the Surflex-Dock software (SYBYL®8.1 mo-
lecular modeling software, Tripos, USA). Crystal structure of the SOAR domain was re-
trieved from the RCS B Protein Data Bank (http://www.pdb.org/, PDB entry code: 3TER) 
(34). The molecule was sketched and minimized using Powell optimization in the presence 
of the Tripos force field with a convergence criterion of 0.001 kcal mol–1 Å–1 and then as-
signed with Gasteiger-Hückel charges. Automatic docking was employed. Other param-
eters were established by default in the software.
Statistics
All statistics were obtained using SPSS statistics 18 software. A one-way analysis of 
variance (ANOVA) followed by a post hoc test was performed to evaluate the effects of 
different groups.
RESULTS AND DISCUSSION
Xyloketals decrease SOCE in PASMCs from C57BL/6 mice
SOCE is the main way of extracellular Ca2+ entry in regulating calcium signaling and 
cellular responses of pulmonary arterial smooth muscle cells (PASMCs). In the present 
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study, we compared the decrease of [Ca2+]i due to SOCE of selected xyloketals in PASMCs 
isolated from C57BL/6 mice. SOCE amplitude was measured by a standard protocol (16, 19) 
using fura-2 dye and fluorescent microcopy in PASMCs perfused with a Ca2+-free Krebs-
Ringer bicarbonate solution containing 10 µmol L–1 cyclopiazonic acid (CPA) and 5 µmol 
L–1 nifedipine (Fig. 2a). CPA is an inhibitor of sarco (endoplasmic) reticulum Ca2+-Mg2+-
ATPase (SERCA) and induces store depletion. Nifedipin is an inhibitor of cell membrane 
L-type voltage-dependent calcium channels (VDCCs) and prevents calcium entry into the 
cell. Five minutes following perfusion of PASMC with these two inhibitors, [Ca2+]i got a 
transient rise, then declined to a steady state, while restoration of extracellular Ca2+ in-
duced a second increase in [Ca2+]i (Fig. 2a). The results showed that xyloketal A (1) could 
effectively inhibit the SOCE resulting from restoration of extracellular [Ca2+]i (p < 0.05 
compared to the control) (Fig. 2a,b). Figs. 2c,d show that [Ca2+]i decreased in the SOCE peak 
and steady-state when xyloketal A (5 µmol L–1) was applied. The same concentration of 
xyloketal A inhibited SOCE by > 61 % in PASMCs compared to the decrease in steady-state 
[Ca2+]i (p < 0.01). The plateau phase could be markedly reduced when SOCE was blocked 
with xyloketal A in PASMCs. These evidences suggested that xyloketal A exerts a promis-
ing SOCE inhibition. Comparing the structures of xyloketals, the tetrahydrofuran-benzo-
pyrane moiety in xyloketal A was highlighted as an important segment for good activity 
that might be a determinant factor for the inhibiting effect of SOCE. Moreover, xyloketal 
A, a unique ketal compound with C-3 symmetry, possesses better lipid solubility com-
pared to other xyloketals, which makes xyloketal A a promising compound for further 
evaluation.
Fig. 2. Drug treatment enhances store-operated Ca2+ entry (SOCE) in PASMCs: a) representative trace 
showing changes in cytosolic Ca2+ concentration, b) representative records showing the amplitude of 
SOCE in control cells (left), and xyloketal-treated PASMCs (right), c) the peak of xyloketal A-operated 
Ca2+ entry (SOCE-peak), d) SOCE plateau phase. Data are expressed as mean ± SEM (n = 5). Significant 
difference vs. control: * p < 0.05, ** p < 0.01.
a)                                                                                           b)
c)                                                                                          d)
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Xyloketal A down-regulated IL-8 secretion in human lung epithelial cells
IL-8 is an important proinflammatory chemokine in airway epithelia, which contribu-
tes to the exaggerated inflammatory state of cystic fibrosis (CF) airways (31). The SOCE 
pathway through ORAI1 activation modulates IL-8 secretion in human airways and may 
contribute to the exaggerated inflammatory response in airway disease with an inflamma-
tory component (32). Since lung inflammation has been well documented after cigarette 
smoke exposure, IL-8 is an important marker in early inflammation and is crucial for 
neutrophil recruitments common in PAH related diseases (33). As shown in Fig. 3, in our 
experiments xyloketal A reduced IL-8 secretion (simulated by CSE) in human epithelial 
cells (Beas-2b and 16HBE), indicating the anti-inflammatory effect of xyloketal A.
The parallel artificial membrane permeability assay (PAMPA)
The parallel artificial membrane permeability assay (PAMPA) is a dynamic model to 
study the passive diffusion of drugs through membranes and is an important assay to 
screen the permeability of new medicines. Using the PAMPA system, we investigated the 
permeability of xyloketals 1-4, whereas verapamil, atenolol and ciprofloxacin were used as 
positive controls. The obtained results are listed in Table I. When compared to three posi-
tive controls, which moderately or hardly permeated EGG-PAMPA and HDM-PAMPA, the 
four examined xyloketals easily permeated EGG-PAMPA and moderately permeated 
HDM-PAMPA. These results implicate that the tested xyloketals easily penetrated through 
the cell membrane and thus might have had a certain effect on SOCE.
Molecular docking studies of 3TER and xyloketal A
Two protein molecules, stromal interaction molecule 1 (STIMl) and calcium release-
activated calcium modulator 1 (ORAI1), are involved in SOCE. Since SOCE is activated 
through dynamic interplay between STIM1 and ORAI1 helices (18), previous studies have 
identified cytosolic regions within STIM1-C protein, defined as the STIM1-ORAI1-activat-
ing region (SOAR, amino acids sequence 344-442) (34). To gain the structural basis for xy-
Fig. 3. Xyloketal A inhibited the IL-8 secretion from lung epithelial cells: a) Beas-2b and b) 16HBE in-
duced by 2 % CSE. Data are expressed as mean ± SEM (n = 5). Significant difference vs. control: * p < 0.01.
a)                                                                           b)
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loketal A bound to SOAR, we performed computer simulations of molecular docking 
 between xyloketal A and the crystal structure of SOAR (3TER). As known, the residue 
 lysine 363 (LYS363) is one of the active sites of 3TER. Our results showed that xyloketal A 




1 –4.93 ± 0.06 (easily) –4.33 ± 0.08 (moderately)
2 –4.03 ± 0.08 (easily) –3.42 ± 0.08 (easily)
3 –4.01 ± 0.12 (easily) –3.86 ± 0.12 (easily)
4 –4.25 ± 0.005 (easily) 3.14 ± 0.03 (easily)
Verapamil –4.96 ± 0.10 (easily) –4.96 ± 0.18 (easily)
Atenolol –7.14 ± 0.13 (hardly) –6.43 ± 0.02 (hardly)
Ciprofloxacin –5.12 ± 0.08 (moderately) –4.64 ± 0.08 (easily)
Fig. 4. Docking conformation between xyloketal A and 3TER. a) Docking model of xyloketal A to-
gether with 3TER, b) docking conformation between xyloketal A and 3TER in the Connolly mode, c) 
molecular docking model of xyloketal A inside an active site (5 Å) of 3TER, d) the key binding bonds 
of xyloketal A with the amino-acid residues of 3TER.
a)                                                                                b)
c)                                                                               d)
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could bind with this residue in the pocket and may generate non-covalent interaction with 
the oxygen atom of the tetrahydrofuran-benzopyrane moiety (Fig. 4), and that the distance 
between this active residues and xyloketal A was about 5 Å.
CONCLUSIONS
Xyloketals have been reported to be protective agents against a variety of pathophysio-
logical stimuli. Their unusual molecular structures possess calcium channel blocking 
 activities. Store-operated calcium entry (SOCE) plays an important role in the develop-
ment of chronic hypoxic pulmonary hypertension. We have proven that xyloketal A, a 
unique compound with C-3 symmetry, is a SOCE blocker. At the same time, a parallel 
 artificial membrane permeability assay (PAMPA) experiment has proven that it is easily 
transported through the cell membrane. Our results suggest that xyloketal A might be a 
new candidate for the treatment of PAH.
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